| |
| |
|
| Insider
Information: |
Wierenga Wendall D |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
167,585 |
|
|
Indirect Shares
|
15,373 |
|
|
| Direct
Value |
$7,596,524 |
|
|
|
Indirect Value
|
$1,634 |
|
|
| Total
Shares |
182,958 |
|
|
| Total
Value |
$7,598,158 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 122.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
EVP, Research & Develo... |
2003-10-10 |
5,023 |
2003-09-01 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
Director |
2013-10-01 |
0 |
2003-11-03 |
0 |
Premium* |
|
|
Xenoport Inc |
XNPT |
Director |
2016-07-05 |
0 |
2006-12-15 |
0 |
Premium* |
|
|
Santarus Inc |
SNTS |
EVP, R&D |
2014-01-02 |
0 |
2014-01-02 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
Director |
2014-03-13 |
12,389 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2014-10-22 |
20,000 |
2017-01-05 |
15,373 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
Director |
2017-12-11 |
0 |
2015-06-23 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-05-15 |
24,327 |
2020-04-28 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2023-06-16 |
105,846 |
2020-04-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
86 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-08-21 |
4 |
OE |
$6.72 |
$40,454 |
D/D |
6,020 |
24,225 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-08-21 |
4 |
S |
$32.02 |
$192,760 |
D/D |
(6,020) |
18,205 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
18,653 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-12-27 |
4 |
AS |
$73.60 |
$736,000 |
D/D |
(10,000) |
18,653 |
0 |
% |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-12-27 |
4 |
OE |
$4.44 |
$44,400 |
D/D |
10,000 |
23,653 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2024-01-02 |
4 |
A |
$84.12 |
$6,225 |
D/D |
74 |
18,727 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2024-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,600 |
24,327 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$150,848 |
D/D |
(4,714) |
0 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$10,048 |
D/D |
(314) |
0 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
EVP, Research & Development |
• – – |
2003-09-01 |
4 |
A |
$53.58 |
$160,740 |
D/D |
3,000 |
3,000 |
|
- |
|
| NBIX |
Neurocrine Biosciences In... |
EVP, Research & Development |
• – – |
2003-10-10 |
4 |
A |
$49.43 |
$99,997 |
D/D |
2,023 |
5,023 |
|
- |
|
86 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
